A- A A+

Treatment History and Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among People Who Inject Drugs. 

Ohlendorf E, Perez-Correa A, Riback L, Ghiroli M, Lopez-Castro T, Fox AD. 

J Addict Med. 2022 Oct 18. doi: 10.1097/ADM.0000000000001093. Epub ahead of print. PMID: 36255107.

Abstract

https://pubmed.ncbi.nlm.nih.gov/36255107/

A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence. 

Greenwald MK, Ghosh S, Winston JR. 

Contemp Clin Trials Commun. 2022 Oct 18;30:101018. doi: 10.1016/j.conctc.2022.101018. PMID: 36303593; PMCID: PMC9593273.

https://www.sciencedirect.com/science/article/pii/S2451865422001351

Association between Prescribers' Perceptions of the Utilization of Medication for Opioid Use Disorder and Opioid Dependence Treatability. 

Adzrago D, Paola AD, Zhu J, Betancur A, Wilkerson JM. 

Healthcare (Basel). 2022 Sep 9;10(9):1733. doi: 10.3390/healthcare10091733. PMID: 36141345; PMCID: PMC9498711.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498711/

Opioid Dose Trajectories and Associations With Mortality, Opioid Use Disorder, Continued Opioid Therapy, and Health Plan Disenrollment. 

Binswanger IA, Shetterly SM, Xu S, et al. 

JAMA Netw Open. 2022;5(10):e2234671. doi:10.1001/jamanetworkopen.2022.34671

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797036

Opioid agonist treatment for people who are dependent on pharmaceutical opioids. 

Nielsen S, Tse WC, Larance B. 

Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD011117. doi: 10.1002/14651858.CD011117.pub3. PMID: 36063082; PMCID: PMC9443668.

Abstract

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011117.pub3/full

Managing Opioid Withdrawal in an Outpatient Setting With Lofexidine or Clonidine. 

Gripshover J, Kosten T. 

Cureus. 2022 Aug 3;14(8):e27639. doi: 10.7759/cureus.27639. PMID: 36072176; PMCID: PMC9437420.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437420/

USA. Opioid Addiction Treatment – A Guide for Patients, Families and Friends

ASAM – American Society of Addiction Medicine, 2016

http://eguideline.guidelinecentral.com/i/706017-asam-opioid-patient-piece/0?

MOUD saves lives, especially after 60 days, and the longer the better. 

Williams, AR. 

Addiction. 2022. doi.org/10.1111/add.16043 

https://onlinelibrary.wiley.com/doi/full/10.1111/add.16043

Opium tincture versus methadone for opioid agonist treatment: A randomized controlled trial, 

Nikoo, M., Kianpoor, K., Nikoo, N., Javidanbardan, S., Kazemi, A., Choi, F., Vogel, M., Gholami, A., Tavakoli, S., Wong, J. S. H., Moazen-Zadeh, E., Givaki, R., Jazani, M., Mohammadian, F., Markazi Moghaddam, N., Schütz, C., Jang, K., Akhondzadeh, S., and Krausz, M. (2022) 

Addiction. doi.org/10.1111/add.16030. 

Abstract

https://onlinelibrary.wiley.com/doi/abs/10.1111/add.16030

Comparison of Lapse Rate in Drug Dependent Patients in 2 Methods of Methadone Maintenance Treatment and Buprenorphine Maintenance Treatment. 

Vafaeinasab M, Zare H, Dehghani A, Malek S, Dehghani-Tafti M, Sarebanhassanabadi M. 

Subst Abuse. 2022 Jul 22;16:11782218221112502. doi: 10.1177/11782218221112502. PMID: 35903309; PMCID: PMC9315257.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315257/

A highly D3R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D3R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder. 

Galaj E, Bi GH, Klein B, Hempel B, Shaik AB, Gogarnoiu ES, Friedman J, Lam J, Rais R, Reed JF, Bloom SH, Swanson TL, Schmachtenberg JL, Eshleman AJ, Janowsky A, Xi ZX, Newman AH. 

Neuropsychopharmacology. 2022 Jul 25:1–10. doi: 10.1038/s41386-022-01379-1. Epub ahead of print. PMID: 35879349; PMCID: PMC9309443.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309443/

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.

Sadek J, Saunders J. 

BMC Psychiatry. 2022 Jul 30;22(1):516. doi: 10.1186/s12888-022-04175-9. PMID: 35908052; PMCID: PMC9338516.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338516/

The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance. 

Meyers-Pantele SA, Mittal ML, Jain S, Sun S, Rammohan I, Fairbairn N, Milloy MJ, DeBeck K, Hayashi K, Werb D. 

Subst Abuse Treat Prev Policy. 2022 May 19;17(1):39. doi: 10.1186/s13011-022-00470-6. PMID: 35590419; PMCID: PMC9118611.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118611/

The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review. 

Jordan CG, Kennalley AL, Roberts AL, Nemes KM, Dolma T, Piper BJ. 

Pharmacy (Basel). 2022 Apr 19;10(3):48. doi: 10.3390/pharmacy10030048. PMID: 35645327; PMCID: PMC9149874.

https://www.mdpi.com/2226-4787/10/3/48

What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings. 

Hooker SA, Sherman MD, Lonergan-Cullum M, Nissly T, Levy R. 

J Subst Abuse Treat. 2022 May 20:108804. doi: 10.1016/j.jsat.2022.108804. Epub ahead of print. PMID: 35643586.

Abstract

https://pubmed.ncbi.nlm.nih.gov/35643586/

What factors influence retention in buprenorphine and methadone treatment?

Medication treatments for opioid use disorder are effective lifesaving therapies, and studies suggest that longer treatment durations result in better patient outcomes (e.g., reduced overdose death risk, less use of ambulatory care services). Identifying the factors that best predict retention can ultimately help us develop and roll out strategies to enhance retention. In this study, the researchers examined which factors were the strongest predictors of medication retention in an Australian sample. (Recovery Research Institute, USA, 22.04.2022)

https://www.recoveryanswers.org/research-post/factors-influence-retention-buprenorphine-methadone-treatment/

Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials. 

Lim J, Farhat I, Douros A, Panagiotoglou D (2022) 

PLoS ONE 17(3): e0266142. doi.org/10.1371/journal.pone.0266142

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0266142

Review of medication-assisted treatment for opioid use disorder. 

Ghanem N, Dromgoole D, Hussein A, Jermyn RT. 

J Osteopath Med. 2022 Mar 14. doi: 10.1515/jom-2021-0163. Epub ahead of print. PMID: 35285220.

https://www.degruyter.com/document/doi/10.1515/jom-2021-0163/html

Update Suchtmedizin: Neue Optionen in der Substitution

Zu Substitution stehen heute zahlreiche Substanzen und Darreichungsformen zur Verfügung. In den letzten Jahren sind insbesondere retardierte Präparate hinzu gekommen, so dass mittlerweile eine auf individuelle Bedürfnisse zugeschnittene Substitution möglich ist. (Richard Kamm, München, Praxis Concept München, in: hiv&more 4/2021

https://www.hivandmore.de/archiv/2021-4/update-suchtmedizin-neue-optionen-in-der-substitution.shtml

Interim opioid agonist treatment for opioid addiction: a systematic review. 

Samsó Jofra L, Puig T, Solà I, Trujols J. 

Harm Reduct J. 2022 Jan 29;19(1):7. doi: 10.1186/s12954-022-00592-x. PMID: 35090475; PMCID: PMC8800211.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800211/

Opioid agonist treatment for self-harm and suicide prevention

Nestadt, Paul S et al.

The Lancet Psychiatry, Volume 9, Issue 2, 100 - 101 

Abstract

https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00448-X/fulltext

A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder. 

Chawar C, Hillmer A, Sanger S, D'Elia A, Panesar B, Guan L, Xie DX, Bansal N, Abdullah A, Kapczinski F, Pare G, Thabane L, Samaan Z. 

Addict Sci Clin Pract. 2021 Nov 27;16(1):70. doi: 10.1186/s13722-021-00278-y. PMID: 34838141; PMCID: PMC8627063.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627063/

Cost-effectiveness of Treatments for Opioid Use Disorder. 

Fairley M, Humphreys K, Joyce VR, et al. 

JAMA Psychiatry. 2021;78(7):767–777. doi:10.1001/jamapsychiatry.2021.0247

https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2778020

Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone. 

Agin-Liebes G, Huhn AS, Strain EC, Bigelow GE, Smith MT, Edwards RR, Gruber VA, Tompkins DA.

Drug Alcohol Depend. 2021 Sep 1;226:108869. doi: 10.1016/j.drugalcdep.2021.108869. Epub 2021 Jun 25. PMID: 34216862.

https://www.sciencedirect.com/science/article/abs/pii/S0376871621003641

High-dose intravenous hydromorphone for patients who use opioids in the hospital setting: time to reduce the barriers.

Labonté, L.E., Young, S. 

Harm Reduct J 18, 87 (2021). doi.org/10.1186/s12954-021-00533-0

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-021-00533-0

Treatment of opium addiction in persian medicine: A review study. 

Kamali M, Kamali H, Doustmohammadi M, Sheikhbardsiri H, Moghadari M. 

J Educ Health Promot. 2021 May 20;10:157. doi: 10.4103/jehp.jehp_5_21. PMID: 34222532; PMCID: PMC8224515.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224515/

USA. TIP 63: Medications for Opioid Use Disorder - Executive Summary

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, 10.08.2021)

https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-003.pdf

USA. TIP 63: Medications for Opioid Use Disorder - For Healthcare and Addiction Professionals, Policymakers, Patients, and Families - Full Document

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, Juli 2021)

https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf

Opium tincture-assisted treatment for opioid use disorder: A systematic review. 

Noroozi A, Kebriaeezadeh A, Mirrahimi B, Armoon B, Ahounbar E, Narenjiha H, Salehi M, Karamouzian M. 

J Subst Abuse Treat. 2021 Jun 4;129:108519. doi: 10.1016/j.jsat.2021.108519. Epub ahead of print. PMID: 34119894.

Abstract

https://pubmed.ncbi.nlm.nih.gov/34119894/

A novel maintenance therapeutic for Opioid Use Disorder. 

Youngblood B, Li K, Gehlert DR, Medina JC, Schwartz N.

J Pharmacol Exp Ther. 2021 May 19:JPET-AR-2020-000214. doi: 10.1124/jpet.120.000214. Epub ahead of print. PMID: 34011529.

https://jpet.aspetjournals.org/content/jpet/early/2021/05/19/jpet.120.000214.full.pdf